当前位置:首页 >财报库 > 报告详情

玛莱克琳生物技术公司Moleculin Biotech, Inc.(MBRX)美股招股说明书 S-1(2025-06-06版)(英文版)(56页).pdf

上传人: 白**** 编号:711611 2025-06-09 56页 1.12MB

下载:

1、S-1/A 1 mbrx20250605_s1a.htm FORM S-1/A Table of Contents As filed with the U.S.Securities and Exchange Commission on June 6,2025.Registration No.333-287727 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 AMENDMENT NO.1 TOFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1

2、933 Moleculin Biotech,Inc.(Exact name of registrant as specified in its charter)Delaware283447-4671997(State or other jurisdiction of(Primary Standard Industrial(I.R.S.Employerincorporation or organization)Classification Code Number)Identification Number)5300 Memorial Drive,Suite 950Houston,Texas 77

3、007(713)300-5160(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Walter V.Klemp,Chief Executive Officer and Chairman5300 Memorial Drive,Suite 950Houston,Texas 77007(713)300-5160(Name,address,including zip code,and telephone number,includ

4、ing area code,of agent for service)Copies to:Cavas S.PavriJohnathan C.DuncanArentFox Schiff LLP1717 K Street NWWashington,DC 20006Telephone:(202)857-6000Fax:(202)857-6395Charles Phillips,Esq.Ellenoff Grossman&Schole LLP1345 Avenue of the Americas,11th FloorNew York,New York 10105Phone:(212)370-1300

5、Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective dateof this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant toRule 415 under the Securities Act of 1933

6、,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list the Securities Act registration statement number of the earlier effective registration2025/6/9 10:52mbrx20250605_s1

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,全文主要概括如下: 1. Moleculin Biotech公司是一家专注于晚期药物开发的公司,目前正在进行Annamycin药物的关键三期临床试验,用于治疗复发/难治性急性髓细胞白血病。 2. 公司计划通过本次发行最多1069万股普通股和3260万股系列E认股权证,以及最多1069万份预付权证,筹集资金约680万美元,用于推进Annamycin和其他药物的研发。 3. 公司聘请Roth Capital Partners作为本次发行的独家配售代理,配售代理将尽力安排证券的销售,但不承担购买或销售任何特定数量或金额的证券。 4. 公司目前不符合纳斯达克的持续上市要求,需要提交合规计划,否则可能会被退市,对公司财务状况和股东权益产生重大不利影响。 5. 投资者购买公司证券将面临重大风险,包括公司无法获得认股权证发行所需的股东批准,以及公司无法获得额外资金支持运营等风险。
安娜霉素的心脏毒性风险如何? 本次股票发行对投资者有何影响? 公司如何使用本次发行的净收益?
客服
商务合作
小程序
服务号
折叠